Gerald J. Clesham

Gerald J. Clesham

Auto-generated profile, based on publicly available information

Gerald J. Clesham

Essex Cardiothoracic Centre, Basildon University Hospital, Basildon, UK

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2024 in Circulation
Verified
Journal Article
Open access
AMAndrew Morrow
Andrew Morrow
RYRobin Young
Robin Young
GAGeorge R. Abraham
George R. Abraham
SHStephen Hoole
Stephen Hoole
JGJohn P. Greenwood
John P. Greenwood
TGThe PRIZE Study Group
The PRIZE Study Group
BACKGROUND: Microvascular angina is associated with dysregulation of the endothelin system and impairments in myocardial blood flow, exercise capacity, and health-related quality of life. The G allele of the noncoding single nucleotide polymorphism RS9349379 enhances expression of the endothelin-1 gene ( EDN1 ) in human vascular cells, potentially increasing circulating concentrations of Endothelin-1 (ET-1). Whether zibotentan, an oral ET-A receptor selective antagonist, is efficacious and safe for the treatment of microvascular angina is unknown. METHODS: Patients with microvascular angina were enrolled in this double-blind, placebo-controlled, sequential crossover trial of zibotentan (10 mg daily for 12 weeks). The trial population was enriched to ensure a G allele frequency of 50% for the RS9349379 single nucleotide polymorphism. Participants and investigators were blinded to genotype. The primary outcome was treadmill exercise duration (seconds) using the Bruce protocol. The primary analysis estimated the mean within-participant difference in exercise duration after treatment with zibotentan versus placebo. RESULTS: A total of 118 participants (mean±SD; years of age 63.5 [9.2]; 71 [60.2%] females; 25 [21.2%] with diabetes) were randomized. Among 103 participants with complete data, the mean exercise duration with zibotentan treatment compared with placebo was not different (between-treatment difference, −4.26 seconds [95% CI, −19.60 to 11.06] P =0.5871). Secondary outcomes showed no improvement with zibotentan. Zibotentan reduced blood pressure and increased plasma concentrations of ET-1. Adverse events were more common with zibotentan (60.2%) compared with placebo (14.4%; P <0.001). CONCLUSIONS: Among patients with microvascular angina, short-term treatment with a relatively high dose (10 mg daily) of zibotentan was not beneficial. Target-related adverse effects were common. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04097314.

7 March 2023 in Interventional Cardiology: Reviews, Research, Resources
Verified
Journal Article
Open access
PDF file
SFSamer Fawaz
Samer Fawaz
SKSarosh Khan
Sarosh Khan
RSRupert Simpson
Rupert Simpson
GCGerald Clesham
Gerald Clesham
CCChristopher M Cook
Christopher M Cook
TKThomas Roger Keeble
Thomas Roger Keeble
The landscape of interventional cardiology is ever evolving. Contemporary practice has shifted from a stenosis-centred approach to the total characterisation of both the epicardial and microcirculatory vessels. Microcirculatory dysfunction plays an important role in the pathophysiology of acute and chronic coronary syndromes, and characterisation of the microcirculation has important clinical consequences. Accordingly, the invasive diagnosis of microcirculatory dysfunction is becoming a key feature of the interventional cardiologist’s toolkit. This review focuses on the methodology underpinning the invasive diagnosis of microvascular dysfunction and highlights the indices that have arisen from these methodologies.

22 January 1994 in BMJ
Verified
Journal Article
Open access
GCG J Clesham
G J Clesham
A 34 year old woman with primary infertility for 10 years had in vitro fertilisation, resulting in a twin pregnancy. She was normally fit and well with no history of cardiac disease. At 24 weeks of pregnancy she developed intermittent vaginal bleeding and was admitted to hospital. Initial assessment showed no evidence of uterine activity, but later the same day she developed contractions and the cervix was found to be 2 cm dilated, although the membranes were intact. Preterm labour was diagnosed and a ritodrine infusion was started at a dose of 200 μg/min, given in 500 ml of normal saline every four hours. She was also given dexamethasone (two 12 mg doses) and thyrotrophin releasing hormone (400 μg eight hourly over 48 hours) to improve fetal lung maturation and reduce the risk of hyaline membrane disease.

15 March 2022 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
KKKlio Konstantinou
Klio Konstantinou
JDJohn R. Davies
John R. Davies
OAOsama Alsanjari
Osama Alsanjari
PKPaul A. Kelly
Paul A. Kelly
KTKare H. Tang
Kare H. Tang
GKGrigoris V. Karamasis
Grigoris V. Karamasis
The impact of adjunctive manual thrombus aspiration (TA) in patients with stent thrombosis (ST) treated with percutaneous intervention has not been evaluated in the current era of potent P2Y12 agents and new-generation drug-eluting stents. We sought to assess the effect of TA using data from a large contemporary registry. The study population was derived from the Essex ST Investigation Registry (ESTHIR), which contains all consecutive cases of angiographically determined definite ST undergoing interventional treatment in a tertiary cardiac centre between November 2015 and June 2018. Propensity score matching was performed to match patients who underwent TA (TA group) to those who did not (n-TA group). The study endpoints were final TIMI flow and survival free of cardiovascular death (CD) or target lesion revascularisation (TLR). A total of 128 ST patients were included in the present analysis. The mean age was 65 ± 11 years, and 84% were male. About 90% of the patients presented with STEMI, and 85% had very late ST. Seventy-two patients (56%) underwent TA. After propensity score matching, 30 patients were included in each study group. A higher rate of final TIMI III flow was observed in the TA group (TA vs n-TA group, 100% vs 83%), but this difference did not reach statistical significance (p = 0.052). At 1000 days of follow-up, survival free of CD or TLR was not different between the two groups (p = 0.8). In a propensity-matched population of ST patients undergoing PCI in a contemporary setting, TA was not associated with improved final TIMI flow or long-term cardiovascular outcomes.

1 November 2025 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
AMAnnette Maznyczka
Annette Maznyczka
SASandeep Arunothayaraj
Sandeep Arunothayaraj
ABAdrian P. Banning
Adrian P. Banning
TSThomas Schmitz
Thomas Schmitz
AWAdrian Wlodarczak
Adrian Wlodarczak
FIfor the EBC MAIN (European Bifurcation Club Left Main Coronary Stent) Trial Investigators
for the EBC MAIN (European Bifurcation Club Left Main Coronary Stent) Trial Investigators
BACKGROUND: In the randomized EBC MAIN trial (European Bifurcation Club Left Main Coronary Stent), target lesion revascularization at 3 years poststenting of left main (LM) bifurcations was more frequent with upfront dual-stenting compared with the stepwise provisional approach. Restenosis location and its relation to stent technique are poorly characterized. The aim of this study was to investigate restenosis location after LM bifurcation stenting, and the impact of stent implantation technique. METHODS: Patients from the EBC MAIN trial who underwent target lesion revascularization during the 3-year follow-up had restenosis location assessed by the core laboratory. Restenosis was defined as ≥50% lesion diameter stenosis. RESULTS: Among 48 patients with target lesion revascularization (mean age 70.3±10.6 years, 72.9% men), 31 were randomized to and treated with upfront dual-stenting, while 17 were randomized to the stepwise provisional technique, of whom 4 had dual-stent implantation. The treatment groups therefore comprised 35 dual-stented and 13 single-stented patients. The commonest pattern of subsequent restenosis was isolated ostial circumflex restenosis (58% of patients), regardless of dual- or single-stent implantation. The ostial circumflex was the culprit lesion for target lesion revascularization in 34 (71%) patients overall (dual- versus single-stented patients: 77% versus 54%; P =0.115). During the 3-year follow-up, the mean % diameter stenosis at the circumflex ostium was similar after dual- versus single-stent implantation (64.6% versus 60.5%, coefficient, −0.12 [95% CI, −0.46 to 0.22]; P =0.473). Single stenting from LM to the circumflex artery was associated with worse subsequent mean % diameter stenosis in the ostium of the left anterior descending artery versus single stenting from LM- left anterior descending (49.8% versus 19.8%, coefficient, 0.57 [95% CI, 0.003–1.13]; P =0.049). CONCLUSIONS: The circumflex ostium is the commonest site requiring revascularization after LM bifurcation stenting, irrespective of whether 1 or 2 stents were deployed. Strategies are needed to improve the long-term success of percutaneous coronary intervention to the circumflex artery ostium. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02497014.

2 December 2025 in Circulation
Verified
Journal Article
Open access
CRChristopher A. Rajkumar
Christopher A. Rajkumar
MFMichael J. Foley
Michael J. Foley
FAFiyyaz Ahmed-Jushuf
Fiyyaz Ahmed-Jushuf
SCShayna Chotai
Shayna Chotai
FSFlorentina A. Simader
Florentina A. Simader
RARasha K. Al-Lamee
Rasha K. Al-Lamee
BACKGROUND: Little correlation exists between the burden of ischemia and severity of angina in patients with stable coronary artery disease. This placebo-controlled, n-of-1 study investigated the relationship between ischemia, the collateral circulation, and symptoms in stable coronary artery disease. Additionally, it explored the association between progressive collateral recruitment and ischemic preconditioning. METHODS: Fifty-one participants with severe single-vessel coronary artery disease and angina were recruited. Antianginal medications were stopped, and daily angina symptoms were documented using a dedicated smartphone application (ORBITA [Objective Randomized Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina] app) for 14 days before undergoing invasive pressure wire studies and coronary flow reserve assessment. Each participant then underwent four 60-s episodes of low-pressure balloon occlusion across their coronary stenosis. Each episode was paired with an audiovisually identical placebo inflation in a randomized order. After each episode, participants scored pain intensity on a 10-point scale, and a placebo-controlled pain intensity score was calculated. Collateral flow index was calculated from simultaneous measures of aortic, right atrial, and distal coronary wedge pressure during balloon occlusion. Higher Pr values from Bayesian models indicate a greater likelihood of association. RESULTS: The mean (±SD) age of participants was 63±9 years, and 78% were men. The median (interquartile range) fractional flow reserve was 0.68 (0.57–0.79), the median instantaneous wave-free ratio was 0.80 (0.48–0.89), and the median coronary flow reserve was 1.42 (1.08–1.85). Daily angina frequency showed little correlation with severity of ischemia, as assessed by fractional flow reserve (Somers’ D 0.124, Pr =0.057) or instantaneous wave-free ratio (Somers’ D 0.056, Pr =0.150). However, there was strong evidence of an association between lower fractional flow reserve and instantaneous wave-free ratio values and greater collateral flow (Somers’ D 0.302, Pr =0.998 and Somers’ D 0.316, Pr =0.999, respectively). There was also strong evidence of an association between more collateralization (higher collateral flow index) and lower pain intensity scores (Somers’ D 0.341, Pr =0.999). Finally, pain intensity scores and collateral flow index remained stable between sequential balloon occlusion episodes within individual patients, indicating little evidence of ischemic preconditioning. CONCLUSIONS: Coronary collateralization is associated with ischemic burden and may reduce the intensity of ischemic chest pain. This may explain the nonlinear relationship between stenosis, ischemia, and angina. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04280575.